Smartwatches keep watch on heart side effects of leukemia drugs
NCT ID NCT06211413
First seen Apr 01, 2026 · Last updated May 14, 2026 · Updated 12 times
Summary
This study follows 50 people with chronic lymphocytic leukemia who are starting treatment with acalabrutinib or zanabrutinib. Participants use wearable devices at home to monitor their heart rhythm and blood pressure. The goal is to learn how often these drugs cause high blood pressure or abnormal heart rhythms, helping doctors manage side effects better.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HYPERTENSION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Abramson Cancer Center at University of Pennsylvania
Philadelphia, Pennsylvania, 19104, United States
Conditions
Explore the condition pages connected to this study.